(RTTNews) - Teva Pharmaceutical Industries Limited (TEVA: News ) announced that the U.S. District Court for the District of Delaware has issued a decision in its litigation over the Company's Abbreviated New Drug Application or ANDA to market its generic version of Takeda Pharmaceuticals North America Inc.'s Prevacid (Lansoprazole) SoluTab.

The Court found that Teva's generic lansoprazole orally disintegrating tablets do not infringe U.S. Patent . Teva said that it intends to complete an analysis of the decision before deciding upon its next course of action.
Annual sales of the brand product were about $500 million in the United States for the twelve months that ended June 30, 2009 based on IMS sales data.

Click here to receive FREE breaking news email alerts for Teva Pharmaceutical Industries Ltd and others in your portfolio

by RTT Staff Writer

For comments and feedback: contact editorial@rttnews.com